Home/ Stocks/ ERNA

Ernexa Therapeutics Inc. Common Stock

ERNA XNAS

$7.53 -0.51 (-6.52%) ▼ 15-min delayed

Open

$7.74

High

$8.11

Low

$6.39

Volume

1.46M

Market Cap

$8.78M

About Ernexa Therapeutics Inc. Common Stock

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 5 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-14,084,000	$-2.24
FY 2025	$0	$-14,084,000	$-2.24
Q3 2025	$0	$-1,240,000	$-0.15
Q1 2025	$0	$-8,202,000	$-0.15

Related Market News

No specific coverage for ERNA yet. Check out our latest market news or earnings calendar.

Get ERNA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Ernexa Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.